Advanced prostate cancer, long resistant to immune-based treatments, could soon see a transformative new option as T-cell engager therapies approach regulatory decisions and expanded trials in 2026. This development is part of a broader wave of innovative treatments, including the first FDA-approved drug designed to completely destroy cancer-causing proteins, poised to reach patients this year.
Immunotherapy has revolutionized care for many cancers, but prostate tumours have historically been "immune-cold," evading detection. T-cell engagers (TCEs) are engineered antibodies that physically link a patient's own cancer-killing T cells to tumour cells, forcing an immune attack. Early trials in advanced prostate cancer have shown promise, and newer versions in development aim to reduce the need for frequent hospital visits. Researchers believe these therapies could soon move into earlier stages of disease, potentially increasing cure rates.
Alongside smarter immunotherapies, a fundamental shift in drug design is reaching a milestone. Instead of just blocking harmful proteins, new technologies aim to eliminate them. The first drug using this targeted protein degradation approach, vepdegestrant, is widely expected to receive FDA approval for advanced breast cancer soon. Another related technique, RIPTACs, is entering early trials for lethal prostate cancer. This method binds two proteins inside a cancer cell, inactivating one essential for survival and causing the tumour cell to self-destruct while sparing healthy tissue.
Platform Trials and Targeted Radiation Offer Hope for Tough Cancers
For aggressive brain tumours, where progress has been slow, a pioneering adaptive trial platform is accelerating drug discovery. The 5G study is the world's first such platform for brain tumours, assigning drugs based on a patient's specific tumour genetics. With its first three trial arms open and scaling up, early results are anticipated by year's end. This approach aims to overcome historical challenges like the blood-brain barrier and small patient numbers.
Similarly, radiopharmaceuticals are emerging as a precise weapon for hard-to-treat cancers. These drugs combine a tumour-homing molecule with a potent radioactive isotope, like actinium-225, to deliver lethal radiation directly to cancer cells. Over a dozen Ac-225-labelled therapies are already in human testing. Promising preclinical work at several institutions is focused on bringing new radiopharmaceuticals into trials for aggressive glioblastomas and paediatric brain cancers.
The convergence of these approaches—smarter immunotherapies, protein-destroying drugs, agile trial platforms, and targeted radiation—signals a pivotal year. With multiple therapies nearing approval or entering critical trial phases, 2026 is set to deliver more precise, effective, and kinder treatment options for patients with some of the most challenging cancers.